GlassScriptPhysician profile
Naum Meyerovich
NPI 1790750859
$13,271.07
in general payments reported to CMS, 2019-2025
53 companies · $3,174 in 2025
The $3,174 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,079 · 2020: $531 · 2021: $955 · 2022: $1,661 · 2023: $2,192 · 2024: $2,678 · 2025: $3,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,044.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,794.33 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,316.64 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,143.46 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $880.62 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $754.38 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $654.18 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Sunovion Pharmaceuticals INC. | $565.37 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $522.09 | 2019-2025 | Fanapt |
| Alkermes, INC. | $474.14 | 2019-2025 | Aristada, Lybalvi |
| Aimmune Therapeutics, INC. | $473.45 | 2024-2025 | Zenpep |
| Amgen INC. | $438.91 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $372.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Neurocrine Biosciences, INC. | $343.16 | 2019-2025 | Ingrezza |
| Mylan Specialty L.P. | $242.70 | 2019-2024 | Yupelri |
| Amarin Pharma, INC. | $218.75 | 2019-2023 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naum Meyerovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.